Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Optic Neuritis: full-pipeline trial registry
3 of 6 indexed Optic Neuritis trials are currently recruiting.
Corpus placement: #2,866 of 28,707 conditions by registered trial count.
6 US clinical trials · 3 currently recruiting · #2,866 of 28,707 conditions by registered trial count
Optic Neuritis: 6 US clinical trials tracked, 3 recruiting.
Optic Neuritis is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Anastasia Vishnevetsky, MD, MPH, running 1 of these trials.
Enrollment posture brief
Registry condition optic-neuritis
OPEN 3 | RECR 50% | LATE 2 | EARLY 2 | RANK #2866 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Achalasia (50% recruiting · 8 trials)
Optic Neuritis lists 3 open slots (50% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Optic Neuritis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Optic Neuritis is recruiting above its size-band peers.
3 of 6 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Optic Neuritis research.
Anastasia Vishnevetsky, MD, MPH accounts for 1 of 6 trials (16.7%). 6 distinct sponsors appear on at least one study for this condition label.
-
Typical Optic Neuritis enrolment sits around 155 participants.
Median target enrolment is 155 among the 6 trials that report a genuine target (sentinel values excluded). 2 of those (33.3%) plan for fewer than 100 participants.
-
Optic Neuritis splits between interventional and observational designs.
4 interventional and 2 observational studies make up this index (66.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
6 total, page 1 of 1
Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX)
Mayo Clinic
NCT07100990
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
University of California, San Francisco
NCT02521311
Efgartigimod for the Treatment of Acute Optic Neuritis
Anastasia Vishnevetsky, MD, MPH
NCT06453694
Biobank For MS And Other Demyelinating Diseases
Accelerated Cure Project for Multiple Sclerosis
NCT00445367
The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders
University of Texas Southwestern Medical Center
NCT01623076
Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis
Beth Israel Deaconess Medical Center
NCT00179478
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
| Phase 3 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Optic Neuritis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Optic Neuritis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Optic Neuritis page
6 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Optic Neuritis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Anastasia Vishnevetsky, MD, MPH sponsors the most Optic Neuritis trials on record, review their full trial history before evaluating a specific study. See Anastasia Vishnevetsky, MD, MPH's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Optic Neuritis condition card totals 6 registered trials; most-linked intervention Placebo; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.